Patients with AL) often show altered levels of some immune molecules in their peripheral blood which correlate with cognitive impairment. Downs' syndrome (DS) subjects are at high risk of developing Alzheimer's disease (AD). Here we studied immune molecules, such as interleukin-6 (IL-6), C reactive protein (CRP) and neopterin, in the blood of non demented children with DS to investigate whether altered peripheral immune phenotype could be present in this subjects without dementia, many years before the presentation of clinical signs of cognitive deterioration. Plasma levels of neopterin and IL-6 were measured by commercially available ELISA kits, whereas plasma CRP concentration was evaluated by nephelometric immunoassay technique. We studied a group of 40 patients with DS, 20 healthy controls and 100 patients w ith AD. Plasma levels of IL-6 and CRP were significantly higher in DS than in control children. The increase of IL-6 and CRP from DS children was similar to that found in elderly patients with clinical AD. In the present research we have also studied blood levels of neopterin which were in the normal range either in DS or control. Increased or normal levels of this metabolite have been found in the blood of AD patients. However, increased blood neopterin was likely to be only elevated in patients with advanced clinical stage of AD. Peripheral altered immune phenotype in healthy young subjects with DS might be an early sign of CNS alterations leading many years later to cognitive deterioration and dementia.
Introduction
DS is characterized by the presence of an extra copv of the chromosome 21 or part of it and is the most frequent chromosomal alteration in man ( 1 ). Children with DS suffer many diseases among which cardiovascular diseases, increased susceptibility to infections, leukemia, endocrine alterations, immune defects, nutritional disturbances and mental retardation have clinical relevance (2).
Increased incidence of infections is often associated with the syndrome and immune defects of variable degree regarding either specific and non-specific immunity have been described in children with DS and a precocious deterioration of the thymus dependent branch of the immunity may account for the high incidence of infections and autoimmune diseases (3).
The syndrome is associated with several clinical alterations, a variable grade of mental retardation (2) and an accelerated ageing of different organs and tissues (3). By the fourth decade of life, brains from subjects with DS show many neuropathological features, i.e. neuritic plaques, neurofobrillary tangles and degeneration of the basal forebrain cholinergic neurons, which are considered the pathological hallmarks of AD. and several middle age DS subjects develop clinical dementia (4,5).
Activated astroglia cells surrounding neuropathological lesions in brains from AD patients without DS release cytokines and acute phase proteins (6-8). The production of interleukin-6 (IL-6) is also increased in bra ins trom AD patients (9,10) and IL-6 over-production has been linked to early stages of plaque formation (II).
The above findings contribute to the hypothesis that cytokines and other molecules with immune regulato-ry functions play a primary role in inflammatory reactions associated with degenerative alterations in the AD brain (12, 13) , and that altered immune responses, usually called neuro-inflammation, are associated with the pathogenesis of the disease ( 14) .
Altered immune reactivity is also detectable in the peripheral blood of patients with clinical AD. For instance, elevated levels of IL-1 and IL-6 have been found in AD (15) (16) (17) (18) (19) . However, other investigations have not found increased IL-6 (20, 21) in the blood of AD patients.
Altered immune responses are frequently observed in DS subjects, even at an early age (22. 23) . and have been considered responsible of the high morbidity for infections in the syndrome. A recent investigation has shown that plasma levels of IL-6 correlated with the degree of mental retardation only in DS subjects (24) .
In the present study the relationship between children with DS and blood levels of IL-6, CRP and neopterin were further investigated.
Patients and Methods
Two groups of children were studied: group 1 consisted of 20 apparently healthy controls (age 5-10 years); group 2 consisted of 40 children with trisomy 21 (age 5-10 years). Down's syndrome was assessed by clinical examination and karyotype analysis. Both controls and DS were in good health status. All DS children were living at home and attending first degree schools, showed a mild and variable degree of mental retardation and were free of other pathological conditions at the moment of the study. Comprehension ability was assessed for each DS child, as previously described (23) . DS children were participating to a nutritional study and informed consent was obtained from one parent. Informed consent was also obtained from control's parents. The protocol was approved by Ethics Committee of University of Bologna and by Fondazione Antoniana of Bologna.
Patients with clinical AD (n = 100, age = 69 + 2 years) were selected at University of Milan, Italy. Clinical diagnosis of AD was performed according to DMS-II1-R and NINCDS-ADRDA criteria (25) . Informed consent was obtained from a relative of the AD patient. Only AD and controls without clinical signs of inflammation, normal body temperature and without concomitant inflammatory disease were admitted to the study.
Blood samples were collected from DS subjects, and controls after an overnight fasting at 8.00 a.m. using EDTA as an anticoagulant. Plasma was obtained by centrifugation (1500 g for 15 min), transferred into coded plastic tubes, rapidly frozen and stored at -20° C until analysis.
Interleukin-6 (IL-6) concentrations were evaluated using a Quantikine Enzyme-Linked Immunosorbent Assay (ELISA) kit (R&D Systems, UK), according to the manufacturer's recommendations. The minimum dctcctablc plasma concentration was 0.70 pg/ml for IL-6.
Plasma C reactive protein (CRP) concentration form DS and control children was evaluated by Latex Agglutination Nephelometric Immunoassay (LANIA) technique (Biolatex, Spain). Samples were diluted 1:36 and results were calculated automatically by IMMAGL system. The minimum detectable concentration was 0.4 mg/dl.
Plasma levels of neopterin were measured by commercially available ELISA (BRAHMS, Berlin, Germany).
The results are given as mean ± standard deviation (SD). GraphPad InStat 3.0 software (GraphPad Software, Inc., San Diego, CA, USA) was used to compare data from DS and controls by unpaired t test. A p-value of <0.05 was considered statistically significant.
Results
As shown in (Fig. 1) . plasma levels of IL-6 were higher in DS than in control children (controls: 0.49 ± 0.10: DS: 2.10 ± 1.09 pg/ ml, ρ <0.0001). Blood levels of CRP were higher in DS than in control children, as illustrated in (Fig. 2) (controls 1.34 ± 0.30; DS: 5.64 ± 3.52 mg L. ρ <0.01 ). As shown in (Fig. 3) , plasma le- ry functions play a primary role in inflammatory reactions associated with degenerative alterations in the AD brain (12, 13) , and that altered immune responses, usually called neuro-inflammation, are associated with the pathogenesis of the disease ( 14) . Altered immune reactivity is also detectable in the peripheral blood of patients with clinical AD. For instance, elevated levels of IL-1 and IL 6 have been found in AD (15) (16) (17) (18) (19) . However, other investigations have not found increased IL-6 (20. 21 ) in the blood of AD patients.
Patients and Methods
Two groups of children were studied: group 1 consisted of 20 apparently healthy controls (age 5-10 years); group 2 consisted of 40 children with trisomy 21 (age 5-10 years). Down's syndrome was assessed by clinical examination and karyotype analysis. Roth controls and DS were in good health status. All DS children were living at home and attending first degree schools, showed a mild and variable degree of mental retardation and were free of other pathological conditions at the moment of the study. Comprehension ability was assessed for each DS child, as previously described (23) . DS children were participating to a nutritional study and informed consent was obtained from one parent. Informed consent was also obtained from control's parents. The protocol was approved by Ethics Committee of University of Bologna and by Fondazione Antoniana of Bologna.
Patients with clinical AD (n = 100. age = 69 + 2 years) were selected at University of Milan, Italy. Clinical diagnosis of AD was performed according to DMS-II1-R and NINCDS-ADRDA criteria (25) . Informed consent was obtained from a relative of the AD patient. Only AD and controls without clinical signs of inflammation, normal body temperature and without concomitant inflammatory disease were admitted to the study.
Interleukin-6 (IL-6) concentrations were evaluated using a Quantikine Enzyme-Linked Immunosorbent Assay (ELISA) kit (R&D Systems, UK.), according to the manufacturer's recommendations. The minimum detectable plasma concentration was 0.70 pg/ml for IL-6. Plasma C reactive protein (CRP) concentration form DS and control children was evaluated by Latex Agglutination Nephelometric Immunoassay (LANIA) technique (Biolatex, Spain). Samples were diluted 1:36 and results were calculated automatically by IMMAGE system. The minimum detectable concentration was 0.4 mg/dl.
Plasma levels of neopterin were measured by commercially available ELISA (BRAHMS. Berlin, Germany).
Results
As shown in (Fig. 1) . plasma levels of IL-6 were higher in DS than in control children (controls: 0.49 ± 0.10; DS: 2.10 ± 1.09 pg/ml, ρ <0.0001 ). Blood levels of CRP were higher in DS than in control children, as illustrated in (Fig. 2) (controls 1.34 ±0.30; DS: 5.64 ± 3.52 mg L. ρ <0.01 ). As shown in (Fig. 3) , plasma le- ry functions play a primary role in inflammatory reactions associated with degenerative alterations in the AD brain (12, 13) , and that altered immune responses, usually called neuro-inflammation, are associated with the pathogenesis of the disease ( 14) . Altered immune reactivity is also detectable in the peripheral blood of patients with clinical AD. For instance, elevated levels of IL-1 and IL-6 have been found in AD (15) (16) (17) (18) (19) . However, other investigations have not found increased IL-6 (20, 21) in the blood of AD patients.
Altered immune responses are frequently observed in DS subjects, even at an early age (22, 23) , and have been considered responsible of the high morbidity for infections in the syndrome. A recent investigation has shown that plasma levels of IL-6 correlated with the degree of mental retardation only in DS subjects (24) .
Patients and Methods
Two groups of children were studied: group 1 consisted of 20 apparently healthy controls (age 5-10 years); group 2 consisted of 40 children with trisomy 21 (age 5-10 years). Down's syndrome was assessed by clinical examination and karyotype analysis. Both controls and DS were in good health status. All DS children were living at home and attending first degree schools, showed a mild and variable degree of mental retardation and were free of other pathological conditions at the moment of the study. Comprehension ability was assessed for each DS child, as previouslydescribed (23) . DS children were participating to a nutritional study and informed consent was obtained from one parent. Informed consent was also obtained from control's parents. The protocol was approved by Ethics Committee of University of Bologna and by Fondazione Antoniana of Bologna.
Patients with clinical AD (n = 100, age = 69 + 2 years) were selected at University of Milan, Italy. Clinical diagnosis of AD was performed according to DMS-1I1-R and NINCDS-ADRDA criteria (25) . Informed consent was obtained from a relative of the AD patient. Only AD and controls without clinical signs of inflammation, normal body temperature and without concomitant inflammatory disease were admitted to the study.
Interleukin-6 (IL-6) concentrations were evaluated using a Quantikine Enzyme-Linked Immunosorbent Assay (ELISA) kit (R&D Systems, UK), according to the manufacturer's recommendations. The minimum detectable plasma concentration was 0.70 pg/ml for IL-6. Plasma C reactive protein (CRP) concentration form DS and control children was evaluated by Latex Agglutination Nephelometric Immunoassay (LANIA) technique (Biolatex, Spain). Samples were diluted 1:36 and results were calculated automatically by IMMAGE system. The minimum detectable concentration was 0.4 mg/dl.
Results
As shown in (Fig. 1) , plasma levels of IL-6 were higher in DS than in control children (controls: 0.49 ± 0.10: DS: 2.10 ± 1.09 pg/ ml, ρ <0.0001). Blood levels of CRP were higher in DS than in control children, as illustrated in (Fig. 2) (controls 1.34 ± 0.30; DS: 5.64 ± 3.52 mg L. ρ <0.01 ). As shown in (Fig. 3) , plasma le- 
